Patents by Inventor D. Scott Wilbur
D. Scott Wilbur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230131121Abstract: Disclosed are general and “substantially pure” branched discrete polyethylene glycol constructs useful in attaching to a variety of biologically active groups, for example, preferential locators, as well as biologics like enzymes, for use in diagnostics, e.g. imaging, therapeutics, theranostics, and moieties specific for other applications. In its simplest intermediate state, a branched branched discrete polyethylene glycol construct is terminated at one end by a chemically reactive moiety, “A”, a group that is reactive with a biologic material that creates “A”, which is a biologically reactive group, connected through to a branched core (BC) which has attached at least two dPEG-containing chains, indicated by the solid line, , having terminal groups, which can be charged, non-reactive or reactable moieties and containing between about 2 and 64 dPEG residues.Type: ApplicationFiled: May 27, 2022Publication date: April 27, 2023Inventors: Paul D. DAVIS, D. Scott WILBUR
-
Patent number: 11505525Abstract: Disclosed are general and “substantially pure” branched discrete polyethylene glycol constructs useful in attaching to a variety of biologically active groups, for example, preferential locators, as well as biologics like enzymes, for use in diagnostics, e.g. imaging, therapeutics, theranostics, and moieties specific for other applications. In its simplest intermediate state, a branched discrete polyethylene glycol construct is terminated at one end by a chemically reactive moiety, “A”, a group that is reactive with a biologic material that creates “A”, which is a biologically reactive group, connected through to a branched core (BC) which has attached at least two dPEG-containing chains, indicated by the solid line, , having terminal groups, which can be charged, non-reactive or reactable moieties and containing between about 2 and 64 dPEG residues.Type: GrantFiled: June 23, 2017Date of Patent: November 22, 2022Assignees: Quanta BioDesign, Ltd., University of WashingtonInventors: Paul D. Davis, D. Scott Wilbur
-
Publication number: 20220354974Abstract: Reagents and methods for labeling biomolecules with astatine isotopes in higher oxidation states. The reagents and methods allow for efficient labeling of biomolecules, such as antibodies, without the formation of high molecular weight by products that arise due to 211At-promoted dimerization and higher aggregation of the conjugated biomolecules, and diminish cellular retention of astatine caused by cellular oxidization of the bonded astatine atom in vivo.Type: ApplicationFiled: April 26, 2022Publication date: November 10, 2022Applicant: University of WashingtonInventors: D. Scott Wilbur, Ming-Kuan Chyan, Donald K. Hamlin
-
Publication number: 20200317612Abstract: Disclosed are general and “substantially pure” branched discrete polyethylene glycol constructs useful in attaching to a variety of biologically active groups, for example, preferential locators, as well as biologics like enzymes, for use in diagnostics, e.g. imaging, therapeutics, theranostics, and moieties specific for other applications. In its simplest intermediate state, a branched branched discrete polyethylene glycol construct is terminated at one end by a chemically reactive moiety, “A”, a group that is reactive with a biologic material that creates “A”, which is a biologically reactive group, connected through to a branched core (BC) which has attached at least two dPEG-containing chains, indicated by the solid line, , having terminal groups, which can be charged, non-reactive or reactable moieties and containing between about 2 and 64 dPEG residues.Type: ApplicationFiled: October 10, 2019Publication date: October 8, 2020Applicants: Quanta BioDesign, Ltd, University of WashingtonInventors: Paul D. Davis, D. Scott Wilbur
-
Publication number: 20170313656Abstract: Disclosed are general and “substantially pure” branched discrete polyethylene glycol constructs useful in attaching to a variety of biologically active groups, for example, preferential locators, as well as biologics like enzymes, for use in diagnostics, e.g. imaging, therapeutics, theranostics, and moieties specific for other applications. In its simplest intermediate state, a branched discrete polyethylene glycol construct is terminated at one end by a chemically reactive moiety, “A”, a group that is reactive with a biologic material that creates “A”, which is a biologically reactive group, connected through to a branched core (BC) which has attached at least two dPEG-containing chains, indicated by the solid line, , having terminal groups, which can be charged, non-reactive or reactable moieties and containing between about 2 and 64 dPEG residues.Type: ApplicationFiled: June 23, 2017Publication date: November 2, 2017Inventors: Paul D. Davis, D. Scott Wilbur
-
Publication number: 20160053345Abstract: This disclosure relates to methods for purifying and isolating astatine-211 from bismuth metal. Also disclosed are automated methods for purifying and isolating astatine-211 from bismuth metal.Type: ApplicationFiled: August 21, 2015Publication date: February 25, 2016Inventors: D. Scott Wilbur, Ming-Kuan Chyan, Donald K. Hamlin, Katherine Gagnon, Shigeki Watanabe
-
Patent number: 8951499Abstract: A reagent for conjugation to a biomolecule, wherein the reagent is a single molecule with at least three functional parts and has schematic structure (I): a) wherein a trifunctional cross-linking moiety is coupled to b) an affinity ligand via a linker 1, said affinity ligand being capable of binding with another molecule having affinity for said ligand, to c) an effector agent, optionally via a linker 2, said effector agent exerting its effect on cells, tissues and/or humorous molecules in vivo or ex vivo, and to d) a biomolecule reactive moiety, optionally via a linker 3, said moiety being capable of forming a bond between the reagent and the biomolecule.Type: GrantFiled: September 6, 2006Date of Patent: February 10, 2015Assignees: University of Washington, Glycorex Transplantation ABInventors: D. Scott Wilbur, Bengt E. B. Sandberg
-
Publication number: 20130052130Abstract: Disclosed are general and “substantially pure” branched discrete polyethylene glycol constructs useful in attaching to a variety of biologically active groups, for example, preferential locators, as well as biologics like enzymes, for use in diagnostics, e.g. imaging, therapeutics, theranostics, and moieties specific for other applications. In its simplest intermediate state, a branched discrete polyethylene glycol construct is terminated at one end by a chemically reactive moiety, “A”, a group that is reactive with a biologic material that creates “A”, which is a biologically reactive group, connected through to a branched core (BC) which has attached at least two dPEG-containing chains, indicated by the solid line, , having terminal groups, which can be charged, non-reactive or reactable moieties and containing between about 2 and 64 dPEG residues.Type: ApplicationFiled: August 30, 2012Publication date: February 28, 2013Applicants: UNIVERSITY OF WASHINGTON, QUANTA BIODESIGN, LTD.Inventors: Paul D. Davis, D. Scott Wilbur
-
Patent number: 7141676Abstract: Water-soluble discrete multi-biotin-containing compounds with at least three (3) biotin moieties are disclosed. The water-soluble biotin-containing compounds may additionally comprise one or more moieties that confer resistance to cleavage by biotinidase or that is cleavable in vitro or in vivo. The discrete multi-biotin-containing compounds may include a reactive moiety that provides a site for reaction with yet another moiety, such as a targeting, diagnostic or therapeutic functional moiety. Biotinylation reagents comprising water-soluble linker moieties are also disclosed and may additionally comprise a biotinidase protective group. Methods for amplifying the number of sites for binding biotin-binding proteins at a selected target using multi-biotin compounds also are disclosed.Type: GrantFiled: September 30, 2002Date of Patent: November 28, 2006Assignee: University of WashingtonInventors: D. Scott Wilbur, Pradip M. Pathare, Donald K. Hamlin, Feng Wan
-
Patent number: 6492560Abstract: The present invention provides discrete-length polyethylene glycol and polyethylene glycol containing compounds and methods for their preparation.Type: GrantFiled: September 24, 2001Date of Patent: December 10, 2002Assignee: The University of WashingtonInventors: D. Scott Wilbur, Pradip M. Pathare
-
Publication number: 20020159994Abstract: A method for the conditioning of an extracorporeal device is described, as well as a method for extracorporeal extraction of toxic material from mammalian body fluids in connection with diagnosis or treatment of a mammalian condition or disease, in which methods reagents having the ability to extract toxic material from mammalian body fluids are involved, and an extracorporeal device comprising said reagent.Type: ApplicationFiled: June 15, 2001Publication date: October 31, 2002Inventors: Bengt E.B. Sandberg, D. Scott Wilbur, Rune Nilsson
-
Publication number: 20020091288Abstract: The present invention provides discrete-length polyethylene glycol and polyethylene glycol containing compounds and methods for their preparation.Type: ApplicationFiled: September 24, 2001Publication date: July 11, 2002Applicant: The University of WashingtonInventors: D. Scott Wilbur, Pradip M. Pathare
-
Patent number: 6294697Abstract: The present invention provides discrete-length polyethylene glycol and polyethylene glycol containing compounds and methods for their preparation.Type: GrantFiled: April 17, 1998Date of Patent: September 25, 2001Assignee: The University of WashingtonInventors: D. Scott Wilbur, Pradip M. Pathare
-
Publication number: 20010023288Abstract: A reagent for conjugation to a biomolecule, wherein the reagent is a single molecule with at least three functional parts and has schematic structure (I): wherein a trifunctional cross-linking moiety is coupled to b) an affinity ligand via a linker 1, said affinity ligand being capable of binding with another molecule having affinity for said ligand, to c) an effector agent, optionally via a linker 2, said effector agent exerting its effect on cells, tissues and/or humorous molecules in vivo or ex vivo, and to d) a biomolecule reactive moiety, optionally via a linker 3, said moiety being capable of forming a bond between the reagent and the biomolecule.Type: ApplicationFiled: December 29, 2000Publication date: September 20, 2001Inventors: D. Scott Wilbur, Bengt E.B. Sandberg
-
Patent number: 6083926Abstract: Vitamin B.sub.12 receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are disclosed. The vitamin B.sub.12 receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety linked by a water-solublizing linker.Type: GrantFiled: November 23, 1998Date of Patent: July 4, 2000Assignees: The University of Washington, Receptagen CorporationInventors: A. Charles Morgan, Jr., D. Scott Wilbur, Pradip M. Pathare
-
Patent number: 5869465Abstract: Receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are utilized for the treatment and diagnosis of a variety of disorders in warm-blooded animals, including neoplastic disorders. The receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety.Type: GrantFiled: March 16, 1995Date of Patent: February 9, 1999Assignees: Receptagen Corporation, University of WashingtonInventors: A. Charles Morgan, Jr., D. Scott Wilbur
-
Patent number: 5840880Abstract: Receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway. The receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety.Type: GrantFiled: March 16, 1995Date of Patent: November 24, 1998Assignees: Receptagen Corporation, University of WashingtonInventors: A. Charles Morgan, Jr., D. Scott Wilbur
-
Patent number: 5840712Abstract: Vitamin B.sub.12 receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are disclosed. The vitamin B.sub.12 receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety linked by a water-solublizing linker.Type: GrantFiled: October 19, 1995Date of Patent: November 24, 1998Assignees: Receptagen Corporation, University of WAInventors: A. Charles Morgan, Jr., D. Scott Wilbur, Pradip M. Pathare
-
Patent number: 5739287Abstract: A biotinylated cobalamin, formed from a vitamin B.sub.12 molecule coupled to a biotin molecule, is disclosed. In a preferred embodiment, the vitamin B.sub.12 molecule is cyanocobalamin. The biotin molecule can also be coupled to a rerouting moiety, optionally through a biotin binding protein such as avidin or streptavidin. The biotinylated cobalamin binds to a cell surface receptor, is invaginated, and once internalized affects the receptor trafficking pathway.Type: GrantFiled: March 16, 1995Date of Patent: April 14, 1998Assignees: University of Washington, Receptagen Corp.Inventors: D. Scott Wilbur, Pradip M. Pathare, A. Charles Morgan, Jr.
-
Patent number: 5679322Abstract: Highly iodinated borane and carborane cage molecules, having from 60% to 90% w/w iodine, are disclosed as new and useful X-ray contrast media when combined with a pharmaceutically acceptable carrier. The inclusion of appropriate functional group substituents, such as hydrophilic moieties, increases solubility and lowers toxicity.Type: GrantFiled: February 5, 1996Date of Patent: October 21, 1997Assignee: University of WashingtonInventor: D. Scott Wilbur